Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
OwnerPaul B. Fisher, Swadesh K. Das +4inventors
InventorsPaul B. Fisher, Swadesh K. Das, Rupesh Dash, Devanand Sarkar, Siddik Sarkar, Jolene Windle
Life of this patent
Estimating the term…
Abstract
Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays.
Claims18
A cancer cell comprising a recombinant truncated CCN1 cancer selective promoter having a nucleotide sequence as set forth in SEQ ID NO:
- 1.
A recombinant vector comprising a truncated CCN1 cancer selective promoter having a nucleotide sequence as set forth in SEQ ID NO:
- 1.
A female transgenic mouse, or offspring thereof, comprising a transgene under operational control of a cancer selective truncated CCN1 promoter.
A female compound transgenic mouse, or offspring thereof, comprising
- a transgene under operational control of a cancer selective truncated CCN1 promoter, wherein said transgene encodes a detectable imaging agent, and
- a transgene or genetic mutation that renders said female compound transgenic mouse, or offspring thereof, prone to develop cancer and/or metastatic cancer.
A method of non-invasively imaging cancer cells and metastases in a female transgenic mouse that develops cancer, comprising
- i) providing a transgenic mouse by genetically engineering a mouse to contain and express a detectable imaging agent under operational control of a cancer selective truncated CCN1 promoter;
- ii) providing at least one female compound transgenic mouse by breeding the transgenic mouse provided in step i) to a mouse that is genetically prone to develop cancer;
- and
- iii) non-invasively imaging cancer cells in said at least one female compound transgenic mouse by detecting expression of said detectable imaging agent in cancer cells of said at least one female compound transgenic mouse.
Dependencies are inferred from the claim text.